Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?

by: Dirk Grimm, Mark A Kay

J. Clin. Invest., Vol. 117, No. 12. (3 December 2007), pp. 3633-3641.

View FullText article

DOI, HighWire, Pubmed, Hubmed

Reviews [Write a review of this article]

There are no reviews of this article

Find related articles from these CiteULike users

jyuh, yavanna, faytn

Find related articles with these CiteULike tags

cu, review, rna, rnai

Abstract

With unprecedented speed, RNA interference (RNAi) has advanced from its basic discovery in lower organisms to becoming a powerful genetic tool and perhaps our single most promising biotherapeutic for a wide array of diseases. Numerous studies document RNAi efficacy in laboratory animals, and the first clinical trials are underway and thus far suggest that RNAi is safe to use in humans. Yet substantial hurdles have also surfaced and must be surmounted before therapeutic RNAi applications can become a standard therapy. Here we review the most critical roadblocks and concerns for clinical RNAi transition, delivery, and safety. We highlight emerging solutions and concurrently discuss novel therapeutic RNAi-based concepts. The current rapid advances create realistic optimism that the establishment of RNAi as a new and potent clinical modality in humans is near. 10.1172/JCI34129

@article{citeulike:2169232, abstract = {With unprecedented speed, RNA interference (RNAi) has advanced from its basic discovery in lower organisms to becoming a powerful genetic tool and perhaps our single most promising biotherapeutic for a wide array of diseases. Numerous studies document RNAi efficacy in laboratory animals, and the first clinical trials are underway and thus far suggest that RNAi is safe to use in humans. Yet substantial hurdles have also surfaced and must be surmounted before therapeutic RNAi applications can become a standard therapy. Here we review the most critical roadblocks and concerns for clinical RNAi transition, delivery, and safety. We highlight emerging solutions and concurrently discuss novel therapeutic RNAi-based concepts. The current rapid advances create realistic optimism that the establishment of RNAi as a new and potent clinical modality in humans is near. 10.1172/JCI34129}, author = {Grimm, Dirk and Kay, Mark A. }, citeulike-article-id = {2169232}, doi = {http://dx.doi.org/10.1172/JCI34129}, journal = {J. Clin. Invest.}, keywords = {rnai}, month = {December}, number = {12}, pages = {3633--3641}, posted-at = {2007-12-26 05:23:40}, priority = {3}, title = {Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?}, url = {http://dx.doi.org/10.1172/JCI34129}, volume = {117}, year = {2007} }

RIS record

TY - JOUR ID - citeulike:2169232 L3 - citeulike-article-id:2169232 N2 - With unprecedented speed, RNA interference (RNAi) has advanced from its basic discovery in lower organisms to becoming a powerful genetic tool and perhaps our single most promising biotherapeutic for a wide array of diseases. Numerous studies document RNAi efficacy in laboratory animals, and the first clinical trials are underway and thus far suggest that RNAi is safe to use in humans. Yet substantial hurdles have also surfaced and must be surmounted before therapeutic RNAi applications can become a standard therapy. Here we review the most critical roadblocks and concerns for clinical RNAi transition, delivery, and safety. We highlight emerging solutions and concurrently discuss novel therapeutic RNAi-based concepts. The current rapid advances create realistic optimism that the establishment of RNAi as a new and potent clinical modality in humans is near. 10.1172/JCI34129 IS - 12 JF - J. Clin. Invest. EP - 3641 TI - Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? VL - 117 SP - 3633 KW - rnai AU - Grimm, Dirk AU - Kay, Mark PY - 2007/12/03/ UR - http://dx.doi.org/10.1172/JCI34129 ER -

RIS BibTeX